KEQU vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KEQU presents a contradictory profile where a stable Piotroski F-Score (4/9) is overshadowed by a severe collapse in earnings growth (-48.90% YoY) and a dismal earnings track record (0/3 beats). While the current price of $34.92 sits below the Graham Number ($45.43), it trades at a premium to its growth-based intrinsic value of $26.04. The combination of a 0/100 technical trend and aggressive insider selling by both the CEO and CFO suggests a lack of confidence in near-term recovery. Despite a low trailing P/E, the rising forward P/E indicates that the market expects further earnings deterioration.
Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.
Compare Another Pair
Related Comparisons
KEQU vs TSLA: Head-to-Head Comparison
This page compares Kewaunee Scientific Corporation (KEQU) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.